Humacyte Balance Sheet Health
Financial Health criteria checks 3/6
Humacyte has a total shareholder equity of $36.0M and total debt of $66.7M, which brings its debt-to-equity ratio to 185%. Its total assets and total liabilities are $162.6M and $126.5M respectively.
Key information
184.95%
Debt to equity ratio
US$66.66m
Debt
| Interest coverage ratio | n/a |
| Cash | US$62.85m |
| Equity | US$36.04m |
| Total liabilities | US$126.51m |
| Total assets | US$162.55m |
Recent financial health updates
Is Humacyte (NASDAQ:HUMA) A Risky Investment?
May 21
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Recent updates
Is Humacyte (NASDAQ:HUMA) A Risky Investment?
May 21Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Mar 24Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
Jan 08Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Dec 23Humacyte: FDA Waiting Game Bleeding Company Dry
Dec 14Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Financial Position Analysis
Short Term Liabilities: HUMA's short term assets ($73.7M) exceed its short term liabilities ($20.0M).
Long Term Liabilities: HUMA's short term assets ($73.7M) do not cover its long term liabilities ($106.5M).
Debt to Equity History and Analysis
Debt Level: HUMA's net debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: HUMA's debt to equity ratio has increased from 0.7% to 185% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HUMA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HUMA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 7.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 19:51 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Humacyte, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |